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Introduction: We investigated the relationship between predominant 
subtype, according to the International Association for the Study of 
Lung Cancer/American Thoracic Society/European Respiratory 
Society International Multidisciplinary Lung Adenocarcinoma 
Classification; mutation status; and patient outcome in stage III (N2) 
lung adenocarcinoma.
Methods: We identified 69 patients with stage III (N2) lung adenocar-
cinoma operated on with curative intent between 1993 and 2011 who 
had adequate tumor tissue for molecular analysis and adequate follow-
up time for survival analysis. DNA was isolated and tested for mutations 
using Sequenom’s OncoCarta Panel (v1.0; Sequenom, San Diego, CA).
Results: The majority of tumors were acinar (26 of 69 tumors; 
38%), solid (24 of 69 tumors; 35%), and micropapillary predomi-
nant (13 of 69 tumors; 19%) subtypes. EGFR and KRAS mutations 
were identified in 17 of 59 tumors (29%) and 13 of 59 tumors (22%), 
respectively. EGFR mutations occurred most often in acinar (11 of 
25 tumors; 44%) and micropapillary predominant tumors (five of 13 
tumors; 38%) (p = 0.009), whereas KRAS mutations occurred most 
often in solid predominant tumors (nine of 21 tumors; 43%) (p = 
0.016). Patients with acinar predominant tumors had significantly 
improved overall survival compared with those with non-acinar 
predominant tumors (hazard ratio: 0.45; 95% confidence interval: 
0.22–0.91; p = 0.026), which remained significant after adjustment 
for EGFR status, T-stage, sex, and age. Patients with EGFR-mutant 
micropapillary predominant tumors had similar survival to those 
with EGFR-mutant acinar predominant tumors. The predominant 
subtype in the primary tumor was most often seen in the N2 node 
in micropapillary and solid predominant tumors but not in acinar 
predominant tumors.
Conclusions: The predominant subtype in the primary tumor was 
associated with overall survival in resected stage III (N2) lung adeno-
carcinoma and was independent of mutation status. Histologic sub-
typing provides important prognostic information and potentially 
molecular correlates.
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Although the overall incidence of lung cancer is falling in Western countries, it remains the biggest cause of 
cancer mortality.1 Non–small cell lung carcinoma comprises 
80% of all lung cancers, of which adenocarcinoma is now 
the most common subtype.2 Histology has been investigated 
as an independent prognostic factor, but the evidence for 
improved outcomes according to broad non–small cell lung 
carcinoma subtypes remains equivocal. The exception to this 
is in the context of some individual adenocarcinoma subtypes, 
with good outcomes approaching 100% 5-year survival in 
adenocarcinoma in situ, formerly known as bronchioloalveolar 
carcinoma3–5 and poor outcomes in micropapillary pattern6–8 
and solid pattern adenocarcinoma.9,10
In response to these issues, a new lung adenocarcinoma 
classification proposed by the International Association 
for the Study of Lung Cancer, American Thoracic Society 
and European Respiratory Society (IASLC/ATS/ERS) 
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has recently been published.11 The importance of the new 
IASLC/ATS/ERS classification is underscored by its prog-
nostic impact that has been recently reported by three stud-
ies,12–14 two of which predominantly examined patients with 
early-stage disease.12,13
As mutations in the EGFR and KRAS genes are 
linked almost exclusively to adenocarcinoma histology, it 
is important to define the associations between these onco-
genic drivers and histologic subtype. Furthermore, the 
presence of activating EGFR mutations has been shown to 
be prognostic for a more favorable outcome independent of 
treatment while also predictive for increased responses to 
tyrosine kinase inhibitor therapy.15–17 Recently, three Asian 
studies18–20 have reported correlations between predomi-
nant subtype in resected lung adenocarcinomas classified 
according to the new IASLC/ATS/ERS classification and 
EGFR mutations.
Because recent studies12–14 validating the prognostic 
impact of the new IASLC/ATS/ERS classification focused 
predominantly on early-stage disease and those correlating 
EGFR mutations and the new classification have only been 
performed in Asian populations,18–20 we sought to examine 
these relationships in a cohort of predominantly Caucasian 
patients with locally advanced lung adenocarcinoma, 
derived from two tertiary Australian centers. To this end, 
we examined 69 patients who underwent surgical resection 
with curative intent and were found to have occult patho-
logic N2 (pN2) lung adenocarcinoma to determine if pre-
dominant subtype correlates with somatic mutations and 
overall survival in more advanced disease. Furthermore, 
we compared predominant subtypes in the primary tumors 
with the histologic patterns in the N2 metastases to deter-
mine whether it is feasible to determine subtype in nodal 




After approval from the human research ethics boards from 
the respective institutions, two surgical registries from tertiary aca-
demic centers linked to the University of Melbourne, Australia (at 
St Vincent’s Hospital and Austin Health), were reviewed to identify 
patients with resected pN2 primary lung adenocarcinoma operated 
on with curative intent between 1993 and 2011.
All patients had pathologically confirmed adenocarci-
noma defined as a malignant epithelial neoplasm with either 
glandular differentiation or mucin production and histopatho-
logic patterns including lepidic, acinar, papillary, micropapil-
lary, and solid with mucin, according to the IASLC/ATS/ERS 
classification.11 In addition, all patients had pathologically 
confirmed N2 nodal disease with metastatic adenocarcinoma 
in one or more of stations 2 to 9, in accordance with the defi-
nitions of the seventh edition of tumor node metastasis clas-
sification of lung cancer staging.21
The definition of a never smoker was a person with a 
lifetime equivalent consumption of fewer than 100 cigarettes. 
None of the patients had neoadjuvant therapy.
Histologic Evaluation
The location, number, and size of tumors were obtained 
from pathology reports. A pathologist (P.R.), blinded to patient 
outcome, reviewed all hematoxylin and eosin–stained slides 
from the 69 cases. An average of six hematoxylin and eosin 
slides of tumor (range, 2–31) were reviewed per case. In 19 
cases, the entire tumor was submitted for histologic examina-
tion and in 56 cases, a block of tumor was submitted per cen-
timeter from the largest dimension of tumor. All cases were 
histologically classified according to the IASLC/ATS/ERS 
classification,11 with estimation in 5% increments of each his-
tologic subtype present and identification and classification of 
each tumor according to the predominant subtype, as previ-
ously described.13 The lowest limit for the predominant sub-
type was set at 30%, as previously described.10,11
All hilar and mediastinal lymph nodes included with 
all 69 cases were examined to assess nodal disease status. All 
histologic patterns present in the lymph node metastases were 
recorded as a binary variable, without assigning percentages. 
It was possible to assign a predominant pattern to the nodal 
metastases in each case.
Mutational Profiling and EGFR and 
KRAS Mutational Analysis
Formalin-fixed, paraffin-embedded blocks with adequate 
tumor tissue was available for 59 cases, from which DNA was 
isolated. The predominant subtype was circled on a glass slide, 
and DNA was isolated either from unstained 10-µm-thick sec-
tions or by punching a 1.5-mm core from the corresponding 
formalin–fixed, paraffin-embedded block. The tissue or core 
was then deparaffinized by serial passages in xylene and alcohol 
and DNA isolated using DNeasy blood and tissue kits (Qiagen, 
Melbourne, Australia) and subjected to mutational profil-
ing using Sequenom’s MassArray platform, OncoCarta Panel 
(v1.0; Sequenom, San Diego, CA), as previously described.22
Follow-up and Outcomes
Of the 69 patients, three patients resected in 2011 were 
excluded from survival analysis as they had less than 12 months 
of follow-up, leaving 66 patients for evaluation of overall sur-
vival. Each patient was followed up till death or for at least 
12 months. One patient died within 30 days of surgery. These 
patients were not part of a trial protocol; however, most patients 
were followed up three monthly for the initial 2 years after 
resection, then six monthly for the subsequent 2 years and annu-
ally following this.
Statistical Analysis
The association between the predominant subtype, 
demographic factors and molecular status was first compared 
with the Fisher’s exact test. Survival analysis was undertaken 
with stratification by predominant subtype/variant according 
to the new IASLC/ATS/ERS classification using the Kaplan–
Meier method by calculating the time from resection to death 
or date of last follow-up. Hazard ratios (HRs) were derived 
using Cox regression analyses, and adjustment was made 
for mutation status, pathologic seventh edition tumor node 
metastasis stage, sex, age, T-stage, and adjuvant chemotherapy.
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RESULTS
Patient and Tumor Characteristics
This data set of 69 patients with resected pN2 lung ade-
nocarcinoma comprised 38 women (55%), with a median age 
of 65.3 years (range, 29–85 years), and 16 current, 34 former, 
and 19 never smokers. Median tumor size was 35 mm (range, 
10–110 mm) (Table 1). Sixty-three patients (91%) underwent 
surgical lobectomy, five underwent pneumonectomy, and one 
had a segmentectomy, with all undergoing mediastinal lymph 
node dissection. Pathologic stage was stage IIIA in 68 patients 
and stage IIIB in one patient.
Predominant subtype in 69 primary tumors was as fol-
lows: 26 of 69 acinar (38%), 24 of 69 solid (35%), 13 of 69 
micropapillary (19%), four of 69 papillary (6%), and two of 
69 colloid (2%) tumors (Table 1). There were no lepidic pre-
dominant tumors.
Correlation of Mutational Profile 
and Predominant Subtype
Mutational profiles were available for 59 patients. 
EGFR and KRAS mutations were identified in 17 of 59 
tumors (29%) and 13 of 59 tumors (22%), respectively 
(Supplementary Table 1, Supplemental Digital Content 1, 
http://links.lww.com/JTO/A381). EGFR mutations occurred 
most often in acinar predominant (11 of 25 [44%]) and 
micropapillary predominant tumors (five of 13 [38%]) 
compared with solid predominant tumors (one of 21 [5%]) 
(p = 0.009) (Table 1). In contrast, KRAS mutations occurred 
most often in solid predominant tumors (nine of 21 [43%]) 
compared with acinar predominant (three of 25 [12%]) and 
micropapillary predominant tumors (one of 13 [8%]) (p = 
0.016) (Table 1).
Correlation of Predominant Subtype 
and Patterns in Primary Tumor and 
Corresponding N2 Metastases
For 69 patients, the N2 metastases showed an admixture 
of histologic patterns (Fig. 1). Although a predominant pattern 
could be identified in all the cases, it was not possible to 
semiquantify each histologic pattern as a percentage. As evident 
from Table 2, the predominant subtype in a primary tumor was 
most often seen in the N2 metastases in micropapillary and 
solid predominant primary tumors, though, for two of 24 (8%) 
solid predominant primary tumors, the N2 metastases showed 
predominantly micropapillary pattern tumor. For 11 of 26 
acinar predominant primary tumors (42%), the N2 metastases 
showed predominantly acinar tumor, but for the remaining 
15 of 26 acinar predominant primary tumors (58%), the N2 
metastases contained predominantly micropapillary (eight of 
15) or solid (seven of 15) pattern tumor. In most cases, if the 
predominant pattern in the lymph node was discordant from the 
predominant subtype in the primary tumor, the predominant 
pattern in the lymph node consisted of a secondary pattern 
present in the primary tumor. Both solid predominant primary 
tumors with predominantly micropapillary tumor in the N2 
metastases showed micropapillary tumor as a secondary 
pattern in the primary tumors (Table 3). Similarly, all eight 
acinar predominant primary tumors with predominantly 
micropapillary tumor in the N2 metastases showed 
micropapillary tumor as a secondary pattern in the primary 
tumors (Table 3). Likewise, six of seven acinar predominant 
primary tumors with predominantly solid tumor in the N2 
metastases showed solid tumor as a secondary pattern in the 
primary tumors, whereas one did not. This latter tumor was 
40 mm and comprised 80% acinar and 20% papillary patterns, 
with only three blocks submitted for histologic examination. 
Furthermore, in all four papillary predominant primary tumors, 
TABLE 1.  Clinical Characteristics and EGFR and KRAS Mutation Status of 69 Patients with Resected Stage III pN2 Lung 
Adenocarcinoma According to the Predominant Subtype
All (n = 69) Acinar (n = 26) Papillary (n = 4) MP (n = 13) Solid (n = 24) Colloid (n = 2) χ2
Median age, years (range) 65.3 (29–85.6) 61.4 (46.7–78.4) 76.9 (71.7–81.4) 68.3 (29–79.9) 65.6 (39.6–85.6) 74.8 (73.8–75.9)
Sex, n 
 Males 31 10 3 6 12 0
 Females 38 16 1 7 12 2
Smoking, n 
 Never 19 10 0 4 4 1
 Former 34 12 3 7 11 1
 Current 16 4 1 2 9 0
Ethnicity, n 
 Asian 8 3 0 3 2 0
 Non-Asian 61 23 4 10 22 2
Median tumor size, mm 
(range)
35 (10–110) 35 (10–90) 75 (25–95) 35 (20–80) 40 (11–110) 36 (35–37)
EGFR/KRAS mutation results (n = 59)
EGFR-positive 17 11 0 5 1 0 p = 0.009
KRAS-positive 13 3 0 1 9 0 p = 0.016
MP, micropapillary.
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the N2 metastases contained predominantly micropapillary 
tumor, with micropapillary pattern present as a secondary 
pattern in all four tumors, and in two colloid predominant 
primary tumors, the N2 metastases contained mostly acinar 
tumor, with acinar pattern present as a secondary pattern in 
both primary tumors (Table 3).
Correlation of Predominant Subtype, 
Mutational Profile, and Overall Survival
The median survival on the basis of predominant 
subtype was as follows: 65.5 months for acinar predominant 
tumors, 27 months for micropapillary predominant tumors, 
23.9 months for solid predominant tumors, 14 months for the 
three patients with papillary predominant tumors, and 10.1 
months for the two patients with colloid predominant tumors 
(Fig. 2A). The relationship between overall survival and 
individual predominant subtype/variant did not reach statistical 
significance, most likely due to limited patient numbers. 
Each previous study investigating the prognostic impact of 
the IASLC/ATS/ERS classification combined predominant 
subtypes with similar survival into three groups, increasing 
their power of analysis.12–14 Hence, we combined patients 
with micropapillary, solid, papillary, and colloid predominant 
tumors into one group on the basis of similar poor survival 
relative to survival in patients with acinar predominant tumors. 
The overall survival of patients with acinar predominant 
tumors was significantly improved compared with those with 
non-acinar predominant tumors (HR: 0.45; 95% confidence 
intervals: 0.22–0.91; p = 0.026) (Fig. 2B). This remained 
significant after adjustment for T-stage, sex and age, and 
EGFR mutation status, a known favorable prognostic factor in 
advanced disease. When adjuvant chemotherapy was included 
in the model, the direction of effect toward improved outcome 











Primary N2 LN metastasis
Acinar Papillary MP Solid Colloid Total 
(%)
Acinar 11 0 8 7 0 26 (38)
Papillary 0 0 4 0 0 4 (6)
MP 0 0 13 0 0 13 (19)
Solid 0 0 2 22 0 24 (35)
Colloid 2 0 0 0 0 2 (2)
Total 13 0 27 29 0 69 (100)
Percentage of 
concordant tumors
42 0 100 92 0 —
A tumor is concordant if the predominant subtype in the primary tumor is present and 
most prominent in the corresponding N2 metastases. Such tumors are indicated in bold.







Secondary pattern in primary tumors
Acinar Papillary MP Solid Colloid
Acinar 2 0 0 0 0
Papillary 0 0 0 0 0
MP 0 0 14 0 0
Solid 0 1 0 6 0
Colloid 0 0 0 0 0
Total 2 1 14 6 0
A tumor is discordant if the predominant subtype in the primary tumor is different 
from the most prominent pattern in the corresponding N2 metastases. For further 
explanation, please see text.
LN, lymph node; MP, micropapillary.
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statistical significance (HR: 0.71, 95% confidence intervals: 
0.23–1.05; p = 0.066).
Given the differences in survival observed on the basis 
the predominant subtype in the primary tumor, we investi-
gated whether the predominant pattern in the N2 node influ-
enced survival. No significant differences were seen on the 
basis of the N2 nodal predominant pattern, indicating that 
the predominant subtype in the primary tumor was the main 
determinant of outcome.
As both acinar and micropapillary predominant subtypes 
displayed divergent prognosis yet harbored EGFR mutations 
at similar rates, we sought to determine whether survival in 
these subgroups was influenced by the presence of mutations. 
Although limited numbers restricted our analyses, patients 
with EGFR-mutant micropapillary predominant tumors had 
similar survival to EGFR-mutant acinar predominant tumors, 
suggesting a less aggressive phenotype in these patients (Fig. 
3; Supplementary Table 2, Supplemental Digital Content 2, 
http://links.lww.com/JTO/A382).
DISCUSSION
These data demonstrate a significant correlation 
between overall survival and predominant subtype accord-
ing to the new IASLC/ATS/ERS lung adenocarcinoma clas-
sification11 in a cohort of patients with advanced-stage lung 
adenocarcinoma. The survival benefit in acinar predominant 
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after adjustment for mutation status but not for adjuvant 
chemotherapy.
We confirm that EGFR-mutant tumors were more likely 
to be either acinar or micropapillary predominant subtypes, 
whereas KRAS-mutant tumors were more often of solid pre-
dominant subtype. When the predominant subtype in the pri-
mary tumor was compared with that in the N2 metastases, 
less than half acinar predominant primary tumors showed 
predominantly acinar pattern in the N2 nodes. However, 
micropapillary and solid predominant primary tumors were 
associated with the same predominant pattern in the N2 
metastases in almost all cases. Despite these differences in 
metastatic potential, the predominant subtype in the primary 
tumor dictated survival differences, not the predominant 
pattern in the N2 metastases.
Of the three recent studies12–14 validating the prognos-
tic impact of the new IASLC/ATS/ERS classification, the one 
from Warth et al.14 includes the largest patient numbers with 
advanced-stage disease. They examined 205 stage I, 105 stage 
II, 162 stage III, and 15 stage IV patients, with 141 stage III 
patients with pN2 disease. Predominant subtype in the 141 
pN2 tumors included two lepidic predominant (1.4%), 57 
acinar predominant (40.4%), 53 solid predominant (37.6%), 
eight papillary predominant (5.7%), and 21 micropapil-
lary predominant (14.9%) tumors. In this larger cohort, the 
percentage of patients with each predominant subtype was 
similar to ours; however, we did not observe any pN2 lepidic 
predominant tumors. Overall survival for 141 pN2 patients 
was 40.5 months in the study by Warth et al. and 26.2 months 
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for 141 pN2 patients according to each separate predominant 
subtype, and it is unclear which patients received adjuvant 
chemotherapy, although they report 71 of 106 stage III/IV 
patients received chemotherapy.
Before the publication of the new IASLC/ATS/ERS 
classification, several studies10,23–25 examined relationships 
between EGFR and KRAS mutations and histologic pattern, 
each study using modifications of the 2004 World Health 
Organization classification2 to classify tumors. Significant 
associations between papillary10 and micropapillary pat-
terns10,23 and EGFR mutations were reported by two groups, 
whereas a third group 24 reported that in a series of 15 micro-
papillary pattern adenocarcinomas, a disproportionately high 
rate of mutations was present, in comparison to results of all 
histologic subtypes from their institution.25
Since the publication of the new IASLC/ATS/ERS clas-
sification, the relationship between EGFR and KRAS muta-
tions and predominant subtype has been examined by two 
Korean studies investigating EGFR mutations and a Chinese 
study examining EGFR, KRAS, HER2, and BRAF mutations 
(Table 4). Shim et al.18 examined 107 resected lung adenocar-
cinomas finding EGFR mutations in 50.5% including 10 of 
12 micropapillary predominant and five of eight lepidic pre-
dominant tumors, with significant associations found between 
EGFR mutations and micropapillary predominant tumors (p = 
0.02) and the presence of any amount of lepidic pattern (p = 
0.02). Sun et al.19 examined 249 resected lung adenocarcino-
mas and found EGFR mutations in 55.4%, including 98 of 173 
acinar predominant, 21 of 30 papillary predominant, and two 
of four micropapillary predominant tumors, but the relation-
ship between acinar and micropapillary predominant tumors 
and EGFR mutations did not reach statistical significance (p 
= 0.06). Zhang et al.20 investigated 349 never-smoking female 
lung adenocarcinoma cases and found EGFR mutations in 
76.2%, including 152 of 183 acinar predominant tumors, with 
a significant association between EGFR mutations and acinar 
predominant histology (p = 0.002). Overall, the results from 
these three Asian studies are similar to our own; however, we 
found EGFR mutations in 29% of tumors. These data suggest 
that in white populations, the predominant subtype enriches 
for specific genotypes.
The significant association between KRAS mutations 
and solid predominant histology is in contrast to the results of 
Zhang et al.,who reported a significant association between 
KRAS mutations and invasive mucinous adenocarcinomas (p 
= 0.028), and Motoi et al.10, who did not find any significant 
associations between histologic subtype and KRAS mutations. 
However, our findings are in line with the results from a North 
American cohort of 82 resected lung adenocarcinomas in which 
27 of 82 tumors harbored KRAS mutations, with 16 of 25 KRAS-
mutant (64%) showing solid predominant histology in compar-
ison to 11 of 57 KRAS-mutant tumors (19%) with non–solid 
predominant histology (p = 0.0002).26 In fact, it appears that 
the frequency of KRAS and indeed EGFR mutations in solid 
predominant histology differs in Asian and Caucasian popula-
tions. This is supported by reports of Asian patients showing 
significant numbers of EGFR mutations in solid predominant 
tumors including 60% of solid predominant tumors in the series 
from Zhang et al.20 and nine of 12 tumors (75%) in a series 
from Sholl et al.27, who examined 65 never-smoking Taiwanese 
women with resected lung adenocarcinoma.
Because of differences in survival between acinar 
predominant and micropapillary predominant subtypes but 
similar frequencies of EGFR mutations, we examined sur-
vival in these two EGFR-mutant histologic subtypes. Patients 
with EGFR-mutant micropapillary predominant tumors had 
similar survival as those with EGFR-mutant acinar predomi-
nant tumors. These findings suggest that acinar predominant 
tumors, although being more likely to harbor EGFR mutations, 
are associated with improved survival regardless of mutation 
status, whereas EGFR wild-type micropapillary predominant 
tumors have the poorest clinical outcome. Therefore, EGFR 
mutations within the micropapillary predominant subtype 
determined a markedly different clinical subgroup compared 
with EGFR wild-type micropapillary predominant tumors 
that were universally associated with poorer outcome.
TABLE 4.  Details of Four Studies Correlating EGFR and KRAS Mutation Status with Predominant Subtype
Number of 
patients Stage EGFR+ (%)
Predom subtype of 
EGFR+ tumors p Value KRAS+ (%)
Predom subtype of 
KRAS+ tumors p Value
Shim et al.18 107 I: 42 54 (50.5) 1. MP (10/12) 0.02 N/A N/A N/A
II: 21 2. Any lepidic (5/8)
III: 44 0.02
Sun et al.19 249 N/S 138 (55.4) 1. Acinar (98/173) 0.06 N/A N/A N/A
2. Papillary (21/30)
3. MP (2/4)




Ang et al.26 82 N/S 17 (21) Nonsolid subtypes N/S 27 (33) Solid with mucin 
(16/25)
0.0002
Survival analysis was not performed in any of these studies.
IMA, invasive mucinous adenocarcinoma; MP, micropapillary predominant adenocarcinoma; N/A, not applicable; N/S, not stated.
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Comparison of the predominant subtype in the primary 
tumor and histologic patterns in the N2 metastases showed 
that both micropapillary and solid patterns were more likely 
to be present in the N2 metastases, despite being present as a 
small percentage in the primary tumor. These findings suggest 
that different metastatic potential exists among adenocarci-
noma subtypes, as proposed by Sica et al.28, who examined 73 
patients with resected lung adenocarcinoma and N1, N2, and 
brain metastases, and also noted that the rates of concordance 
between predominant subtypes in the primary tumors and N2 
metastases suggested differing metastatic potential. On the 
basis of this, we concur that the acinar pattern is of interme-
diate metastatic potential, whereas micropapillary and solid 
patterns are of high metastatic potential.
In conclusion, we report a significant relationship 
between the predominant subtype in the primary tumor, as 
defined by new IASLC/ATS/ERS lung adenocarcinoma clas-
sification, and overall survival in 66 patients with resected 
stage III pN2 lung adenocarcinoma. Athough EGFR muta-
tions occurred more frequently in acinar predominant tumors, 
the improvement in survival occurred independent of muta-
tion status. These findings indicate that the predominant sub-
type in the primary tumor determines outcome in pN2 disease 
but not the predominant pattern in the lymph node or mutation 
status. Subtyping tumors based on the new IASLC/ATS/ERS 
classification provides important prognostic information and 
potentially molecular correlates. Subtyping could be used to 
better personalize treatments toward subgroups most likely to 
derive benefit, a strategy that warrants further investigation in 
prospective studies.
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